Published in Obesity and Diabetes Week, June 19th, 2006
Study 1: Incretin mimetics and dipeptidyl peptidase-IV inhibitors offer potential new therapies for type 2 diabetes mellitus.
According to a recent review from the United States, "The emergence of the glucoregulatory hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide has expanded our understanding of glucose homeostasis. In particular, the glucoregulatory actions of the incretin hormone GLP-1 include enhancement of glucose-dependent insulin secretion, suppression of inappropriately elevated glucagon secretion, slowing of gastric...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week